MYD88 and neoplasm: Pathogenic bacteria in the tumor can activate TLR4 of mesenchymal cells and the MYD88 pathway, releasing the inflammatory factor IL-23, which in turn activates IL-17A, IL-6, and IL-22 to promote the development of CRC [31].